Moya M. Daniels
Plus aucun poste en cours
Profil
Moya M.
Daniels worked as a Director-Prochymal Business Unit at Osiris Therapeutics, Inc. from 2017 to 2019.
Prior to that, she was the VP-Regulatory Affairs & Quality Assurance at Fate Therapeutics, Inc. from 2014 to 2017.
She also held positions at SanBio, Inc. and Macrocure Ltd.
In 2017 to 2019, she worked as the Senior Vice President-Regulatory Affairs at Orchard Therapeutics Plc.
In 2020 to 2021, she was the Executive VP, Head-Regulatory & Quality at Histogen, Inc. Daniels received her undergraduate degree from Saint Augustine's University and her graduate degree from the University of Maryland.
Anciens postes connus de Moya M. Daniels
| Sociétés | Poste | Fin |
|---|---|---|
| HISTOGEN INC. | Chief Tech/Sci/R&D Officer | 01/08/2021 |
| OSIRIS THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2019 |
| ORCHARD THERAPEUTICS PLC | General Counsel | 01/01/2019 |
| FATE THERAPEUTICS, INC. | General Counsel | 01/07/2017 |
SanBio, Inc.
 SanBio, Inc. Medical/Nursing ServicesHealth Services SanBio, Inc. develops regenerative therapies for neurological disorders. The firm is focused on cell therapies for neurological disorders such as stroke, traumatic brain injury, eye disease, and Parkinson's disease. Its product pipeline includes SB623 and SB618. The company was founded by Keita Mori and Toru Kawanishi in 2001 and is headquartered in Mountain View, CA. | Corporate Officer/Principal | - |
Formation de Moya M. Daniels
| Saint Augustine's University | Undergraduate Degree |
| University of Maryland | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| FATE THERAPEUTICS, INC. | Health Technology |
| HISTOGEN INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Osiris Therapeutics, Inc.
 Osiris Therapeutics, Inc. BiotechnologyHealth Technology Osiris Therapeutics, Inc. engages in the research, development, manufacture, and commercialization of regenerative medicine products. Its biosurgery business focuses on using unique tissue preservation technologies to develop viable human tissue products designed to improve wound closure and surgical outcomes for patients and physicians over standard of care alone. The company was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD. | Health Technology |
SanBio, Inc.
SanBio, Inc. Medical/Nursing ServicesHealth Services SanBio, Inc. develops regenerative therapies for neurological disorders. The firm is focused on cell therapies for neurological disorders such as stroke, traumatic brain injury, eye disease, and Parkinson's disease. Its product pipeline includes SB623 and SB618. The company was founded by Keita Mori and Toru Kawanishi in 2001 and is headquartered in Mountain View, CA. | Health Services |
Macrocure Ltd.
 Macrocure Ltd. Medical SpecialtiesHealth Technology Macrocure Ltd. is a clinical-stage biotechnology company, which engages in the development and commercialization of advanced cell therapy products. Its product, CureXcell, is an advanced wound care therapy that treat such wounds by injecting living human white blood cells that have been activate to facilitate the healing process. The company was founded by David Ben-Ami on January 14, 2008 and is headquartered in Petach Tikva, Israel. | Health Technology |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
